Technological Innovation As Power
For Human Health
With Our Wisdom, Passion, Efforts
Committed to Becoming A Highly Regarded and Modern Biopharmaceutical Enterprise
Core Values
Innovation, Pragmatism, Integrity, and Agility
ABOUT PL
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was established in April 2009. It is a high-tech biopharmaceutical enterprise focusing on the research, development and production of peptide drugs and chemical drugs. The company is located in Jiangyin High-tech Development Zone, Jiangsu Province, and is a national high-tech enterprise. There are wholly-owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as subsidiaries Jiangsu Putai Pharmaceutical Technology Co., Ltd. and ProteLight Medical Holdings (Hong Kong) Co., Ltd.
Explore More →
OUR SCIENCE AND PIPELINE
Established a very competitive peptide drug pipeline led by first-in-class anti-infective agents and anti-cancer drugs
-
R&D Center
The company currently has multiple national Class 1 innovative drug research projects and dozens of patents, including PCT international invention patents, US and EU invention patents, Chinese invention patents, utility model and appearance patents, etc.Explore More + -
Targets & Mechanisms of action
The company currently has multiple varieties of national Class 1 innovative drugs under development, with dozens of patents, including PCT international invention patents, US and EU invention patents, etc.Explore More + -
Pipeline
The company continues to be oriented towards innovation and internationalization, increasing investment in research and development and the introduction of scientific research personnel.Explore More +
NEWS
With technological innovation as the power, serving human health!
News
Company News
On October 26, 2024, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. ("ProteLight Pharma") received a Study May Proceed (SMP) letter from the FDA, indicating that the company's innovative Antimicrobial Peptide PL-18 Suppository has been approved for the Phase II clinical study in the United States.
Company News
October 2023, Healthcare Executive Magzine released the lists of “Top 100 Chinese Pharmaceutical Innovative Enterprises in 2023” and “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”.
READ MORE